Kenvue Inc(KVUE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 20.62 | EPS (ttm) | 0.86 | Insider Own | 0.29% | Shs Outstand | 1.92B | Perf Week | -7% |
| Market Cap | 34.17B | Forward P/E | 14.25 | EPS next Y | 6.1% | Insider Trans | -0.75% | Shs Float | 1.92B | Perf Month | -6.61% |
| Enterprise Value | 41.67B | PEG | 1.92 | EPS next Q | 0.29 | Inst Own | 96.34% | Short Float | 2.76% | Perf Quarter | -1.44% |
| Income | 1.66B | P/S | 2.22 | EPS this Y | 8.93% | Inst Trans | 1.14% | Short Ratio | 2.59 | Perf Half Y | 0.79% |
| Sales | 15.41B | P/B | 3.24 | EPS next 5Y | 7.41% | ROA | 6.16% | Short Interest | 52.78M | Perf YTD | 3.13% |
| Book/sh | 5.5 | P/C | 30.78 | EPS past 3/5Y | -10.84% - | ROE | 15.58% | 52W High | -11.62% ($20.13) | Perf Year | -3.68% |
| Cash/sh | 0.58 | P/FCF | 17.85 | Sales past 3/5Y | 0.43% 0.89% | ROIC | 9.36% | 52W Low | 26.89% ($14.02) | Perf 3Y | -16.48% |
| Dividend Est. | $0.85 (4.75%) | EV/EBITDA | 11.81 | EPS Y/Y TTM | 16.81% | Gross Margin | 58.36% | Volatility(W/M) | 2.02% 1.65% | Perf 5Y | - |
| Dividend TTM | 0.83 | EV/Sales | 2.7 | Sales Y/Y TTM | 1.75% | Oper. Margin | 19.24% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/12 | Quick Ratio | 0.71 | EPS Q/Q | 8.86% | Profit Margin | 10.76% | RSI (14) | 31.72 | Recom | 2.87 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.01 | Sales Q/Q | 3.02% | SMA20 | -5.83% ($18.89) | Beta | 0.45 | Target Price | $19.3 |
| Payout | 107.98% | Debt/Eq | 0.82 | Earnings | 2026/8/6 | SMA50 | -6.92% ($19.11) | Rel Volume | 3.16 | Prev Close | $17.75 |
| Employees | 22000 | LT Debt/Eq | 0.68 | EPS/Sales Surpr. | -2.73% -0.27% | SMA200 | -1.06% ($17.98) | Avg Volume(3M) | 20.38M | Price | $17.79 |
| IPO | 2023/5/4 | Option/Short | Yes/Yes | Trades | 55855 | Volume | 64,356,786 | Change | 0.23% |
Company
KVUE is a Consumer Defensive sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧴 This is a consumer health-focused company with a portfolio of global consumer health brands, including Tylenol, Listerine, Neutrogena, Neutrogena, Johnson's, Band-Aid, and Aveeno. Since being spun off from Johnson & Johnson, it has been operating its own consumer health business as a global household goods and personal care company.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
KVUE makes money exceptionally well
19.24% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +8.9% this year.
Tap to view numbers
The price looks about right
Trading at 20.6 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Long-term returns are close to the market
Would have changed by -16.5% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 4.75% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 96.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #4 in the industry
Based on market cap of $34B.
FAQ
What kind of company is KVUE?
KVUE belongs to the Consumer Defensive sector and operates in the Household & Personal Products industry.
What is the market cap of KVUE?
The market cap of KVUE is approximately $34.2B, ranking 426 within its sector.
Does KVUE pay dividends?
KVUE has a dividend yield of approximately 4.75%, with an annual dividend of $0.85.
What is the P/E ratio of KVUE?
KVUE has a P/E ratio of approximately 20.6x, which can be used to assess its valuation relative to the Consumer Defensive sector average.
What is the 52-week high and low for KVUE?
KVUE has recorded a 52-week high of $20.13 and a low of $14.02.